Business Wire

Fortaco Group to be Acquired by One Equity Partners

8.7.2022 14:00:00 EEST | Business Wire | Press release

Share

Funds managed by CapMan Buyout have agreed to sell their holdings in Fortaco Group, the leading strategic partner to the heavy off-highway equipment and marine industries offering technology, vehicle cabins, steel fabrications, and assemblies to global OEMs, to private equity firm One Equity Partners.

As the new owner, One Equity Partners will empower the further development of the current and new offerings of Fortaco, including areas to strengthen value creation to customers and to provide the means for further international expansion.

“We are very honored to become a member of the One Equity Partners family. I want to express my sincere thanks to all our global customers, business partners, and the Fortaco team for the highly qualified performance we reached together. With One Equity Partners, we are looking forward to realizing the full potential of Fortaco as the leading business partner of technology, vehicle cabins, steel fabrications and assemblies. In addition, I want to thank CapMan as the owner and the Board of Directors for their support and trust,” says Lars Hellberg, President & CEO of Fortaco Group.

“We look forward to partnering with Fortaco CEO Lars Hellberg and his team, applying our industrial sector expertise to support Fortaco in broadening and deepening its offerings in current markets and expanding into new end markets where we believe the Company is well-positioned for success,” said Johann-Melchior von Peter, Senior Managing Director at One Equity Partners. “We see ample opportunity for Fortaco to leverage its global manufacturing and sourcing footprint and extend its value to clients by helping them improve their operational efficiency,” adds Marc Lindhorst, Principal at One Equity Partners.

Under the ownership of CapMan, Fortaco has grown and become a market-leading, premium industrial company. Fortaco has factories across seven European countries, in addition to a joint venture with Tata AutoComp in India. Fortaco also has a large portfolio of global customers in different industry segments, and the company’s turnover and profitability have developed very favorably in recent years.

“CapMan was one of the initiators in the formation of Fortaco Group ten years ago. We have provided continuous strategic support over the company’s many development phases towards the market leader it is today with ambitious growth prospects. I would like to thank Fortaco’s management team and employees for excellent co-operation over the years. The company is now well-positioned to continue its growth journey with One Equity Partners as the new owner,” says Anders Björkell, partner at CapMan Buyout.

Closing of the transaction is expected in the second half of 2022 and is subject to regulatory approvals and customary closing conditions.

Fortaco
Fortaco is the leading brand-independent strategic partner to the heavy off-highway equipment and marine industries offering technology, vehicle cabins, steel fabrications and assemblies. Fortaco Group has operations in multiple European and Asian business sites and technology hubs, which are supporting the global customers.

One Equity Partners
One Equity Partners is a middle market private equity firm focused on transformative combinations within the industrial, healthcare and technology sectors in North America and Europe. The firm was founded in 2001 and spun out of JP Morgan in 2015 to become an independent partnership. One Equity Partners has completed more than 300 transactions worldwide with offices in New York, Chicago, Frankfurt and Amsterdam.

CapMan
CapMan is a leading Nordic private assets manager and investor with an active approach to value creation. As one of the private equity pioneers in the Nordics they have built value in unlisted businesses, real estate, and infrastructure for over three decades. With over €4.7 billion in assets under management, their objective is to provide attractive returns and innovative solutions to investors.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information
Lars Hellberg
+358 40 572 9488
lars.hellberg@fortacogroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye